For personal use only
Universal Biosensors, Inc.
ARBN 121 559 993
1 Corporate Avenue
Rowville Victoria 3178
Australia
Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Emailinfo@universalbiosensors.com
www.universalbiosensors.com
28 July 2022
Universal Biosensors, Inc.
June 2022 Quarterly Activity Report
Universal Biosensors, Inc. (ASX:UBI) (UBI) has today released its cash flow report (ASX Appendix 4C) and quarterly activity report for the quarter ended 30 June 2022 (Q2 2022).
UBI is developing and commercializing a range of biosensors in oenology (wine industry), human health including oncology, coagulation, COVID-19, women's health and fertility, non-human and environmental testing using our patented platform technology and hand-held point of use devices.
The primary focus of UBI's activities during the second quarter of 2022 were:
- A$26 million raised pursuant to a A$20 million fully underwritten rights issue and a A$6 million placement, both at A$0.77;
- Sentia quarter on quarter direct sales increased 21% between Q2 2022 and Q1 2022;
- Overall sales of Sentia for H1 2022 were in line with H1 2021;
- Xprecia Prime received regulatory approval to sell in 32 countries in Europe;
- 281 patients have been enrolled in the Xprecia Prime clinical trial in the USA (360 patients required in total);
- UBI established an Ecommerce website for the sale of our suite of Sentia products in the USA;
- UBI appointed a Business Development Manager for Sentia Europe;
- UBI entered into new distribution agreements with Vivelys USA and Vivelys Chile and Vintner Vault (USA) for the sale of Sentia's wine testing platform device;
- Our first Sentia sales order placed in the United Kingdom;
- The finalization of Sentia's Glucose product;
- Ongoing development of Sentia wine testing products;
- The establishment of a distribution centre in the USA to support the global expansion of the Company's wine testing product sales. This is in addition to the distribution centres we have in Australia and Europe;
- The continuing successful development and use of aptamer sensing technology on our hand-held platform device;
- The progression of an Investigational Clinical Study (300 patient/+) for our Tn Antigen biosensor used for the detection, staging and monitoring of cancer;
- The continued development of our blood glucose monitoring product for dogs and cats with diabetes;
- The appointment of a Business Development Director for our Petrackr Blood Glucose Monitor in the USA; and
- The investment into our manufacturing scale-up project which will add an approximate annual 35 million strip.
FINANCIAL UPDATE
Net cash (cash and cash equivalents less short and long-term debt) as at 30 June 2022 was $33.1 million.
Highlights are as follows:
- Receipts from customers during the three months ended 30 June 2022 increased by 39% to $1.4 million compared to the previous corresponding period
- Receipts from customers during the six months ended 30 June 2022 increased by 80% to $2.4 million compared to the previous corresponding period
For personal use only
Universal Biosensors, Inc.
ARBN 121 559 993
1 Corporate Avenue
Rowville Victoria 3178
Australia
Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Emailinfo@universalbiosensors.com
www.universalbiosensors.com
Payments of $86,000 as disclosed in item 6 of the attached Appendix 4C comprised of the non-executive directors' fees, allowances and superannuation.
For further information, please contact:
John Sharman
Chief Executive Officer +61 (0) 414 440 680
Announcement authorised by the Board of Directors of Universal Biosensors, Inc.
For personal use only
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Name of entity
UNIVERSAL BIOSENSORS, INC. | |
ABN | Quarter ended ("current quarter") |
67 950 836 446 | 30 June 2022 |
Consolidated statement of cash flows | Current quarter | Year to date (6 | ||
$A'000 | months) | |||
$A'000 | ||||
1. | Cash flows from operating activities | |||
1.1 | Receipts from customers | 1,381 | 2,402 | |
1.2 | Payments for | |||
(a) | research and development | (1,292) | (2,292) | |
(b) product manufacturing and operating | (861) | (2,107) | ||
costs | ||||
(c) | advertising and marketing | (145) | (422) | |
(d) | leased assets | (311) | (420) | |
(e) | staff costs | (2,495) | (5,176) | |
(f) administration and corporate costs | (756) | (1,760) | ||
1.3 | Dividends received (see note 3) | |||
1.4 | Interest received | 12 | 19 | |
1.5 | Interest and other costs of finance paid | (5) | (11) | |
1.6 | Income taxes paid | |||
1.7 | Government grants and tax incentives | 33 | 33 | |
1.8 | Other (provide details if material) | 37 | 76 | |
1.9 | Net cash from / (used in) operating | (4,402) | (9,658) | |
activities | ||||
2. | Cash flows from investing activities | |||
2.1 | Payments to acquire or for: | |||
(a) | entities | |||
(b) | businesses | |||
(c) property, plant and equipment | (133) | (406) | ||
(d) | investments | |||
(e) | intellectual property | |||
(f) other non-current assets |
ASX Listing Rules Appendix 4C (17/07/20) | Page 1 |
+ See chapter 19 of the ASX Listing Rules for defined terms. |
For personal use only
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows | Current quarter | Year to date (6 | ||
$A'000 | months) | |||
$A'000 | ||||
2.2 | Proceeds from disposal of: | |||
(a) | entities | |||
(b) | businesses | |||
(c) | property, plant and equipment | |||
(d) | investments | |||
(e) | intellectual property | |||
(f) | other non-current assets | |||
2.3 | Cash flows from loans to other entities | |||
2.4 | Dividends received (see note 3) | |||
2.5 | Other (provide details if material) | |||
2.6 | Net cash from / (used in) investing | (133) | (406) | |
activities |
3. Cash flows from financing activities
3.1 Proceeds from issues of equity securities
(excluding convertible debt securities) | 26,007 | 26,007 |
3.2 Proceeds from issue of convertible debt securities
3.3 | Proceeds from exercise of options | 40 | 44 |
3.4 | Transaction costs related to issues of | (993) | (993) |
equity securities or convertible debt | |||
securities | |||
3.5 | Proceeds from borrowings | 0 | 1,002 |
3.6 | Repayment of borrowings | (331) | (777) |
3.7 Transaction costs related to loans and borrowings
3.8 | Dividends paid | ||
3.9 | Other (provide details if material) | (1) | (1) |
3.10 | Net cash from / (used in) financing | 24,722 | 25,282 |
activities |
4. Net increase / (decrease) in cash and cash equivalents for the period
4.1 Cash and cash equivalents at beginning of
period | 13,014 | 18,099 | |
4.2 | Net cash from / (used in) operating | (4,402) | (9,658) |
activities (item 1.9 above) | |||
4.3 | Net cash from / (used in) investing activities | (133) | (406) |
(item 2.6 above) |
ASX Listing Rules Appendix 4C (17/07/20) | Page 2 |
+ See chapter 19 of the ASX Listing Rules for defined terms. |
For personal use only
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows | Current quarter | Year to date (6 | |
$A'000 | months) | ||
$A'000 | |||
4.4 | Net cash from / (used in) financing activities | 24,722 | 25,282 |
(item 3.10 above) | |||
4.5 | Effect of movement in exchange rates on | 230 | 114 |
cash held | |||
4.6 | Cash and cash equivalents at end of | 33,431 | 33,431 |
period | |||
5. | Reconciliation of cash and cash | Current quarter | Previous quarter |
equivalents | $A'000 | $A'000 | |
at the end of the quarter (as shown in the | |||
consolidated statement of cash flows) to the | |||
related items in the accounts | |||
5.1 | Bank balances | 6,556 | 10,784 |
5.2 | Call deposits | 25,000 | |
5.3 | Bank overdrafts | ||
5.4 | Other (provide details) | 1,875 | 2,230 |
The Company maintains restricted cash | |||
which includes tenant security deposits, | |||
credit card security deposits and a letter of | |||
credit issued in favour of a Customer. | |||
5.5 | Cash and cash equivalents at end of | 33,431 | 13,014 |
quarter (should equal item 4.6 above) | |||
6. | Payments to related parties of the entity and their | Current quarter | |
associates | $A'000 | ||
6.1 | Aggregate amount of payments to related parties and their | 86 | |
associates included in item 1 |
6.2 Aggregate amount of payments to related parties and their associates included in item 2
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.
Item 6.1 includes non-executive directors' fees and salaries, allowances and superannuation
ASX Listing Rules Appendix 4C (17/07/20) | Page 3 |
+ See chapter 19 of the ASX Listing Rules for defined terms. |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Universal Biosensors Inc. published this content on 28 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2022 05:57:08 UTC.